project id: TCGA-PRAD; case submitter id: TCGA-VN-A88N; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.67; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.29; rna integrity number: 8.0; age at index: 62; days to birth: -22695; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1951; age at diagnosis: 22695; ajcc clinical m: M0; ajcc clinical t: T1c; ajcc pathologic n: N0; ajcc pathologic t: T2c; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 766.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 3; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 156; initial weight: 50.0; sample id: f5c35097-25b1-4fee-bb32-790b765a20b1; sample submitter id: TCGA-VN-A88N-01A; portion id: e6a9fd05-1289-4bd0-a5c5-8afca5ca08d8; portion submitter id: TCGA-VN-A88N-01A-11; slide id: ee052890-4105-411b-bfb9-b290365fa755; slide submitter id: TCGA-VN-A88N-01A-01-TS1; percent lymphocyte infiltration: 60.0; percent monocyte infiltration: 10.0; percent necrosis: 0.0; percent neutrophil infiltration: 20.0; percent normal cells: 0.0; percent stromal cells: 20.0; percent tumor cells: 80.0; percent tumor nuclei: 80.0; section location: TOP;